Skip to main content

Clinical Trials Using Gemcitabine Hydrochloride

Review the clinical trials studying gemcitabine hydrochloride on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-23 of 23

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Status: Active
Location: 1053 locations
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy before Surgery for Patients with High-Grade Upper Urinary Tract Cancer
Status: Active
Location: 206 locations
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients with Metastatic Triple Negative Breast Cancer
Status: Active
Location: 25 locations
Donor NK Cell Therapy in Combination with Gemcitabine and Docetaxel for the Treatment of Relapsed or Refractory Sarcomas, The TINKS Trial
Status: Active
Location: 22 locations
CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer
Status: Active
Location: 24 locations
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Status: Active
Location: 11 locations
Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
Status: Active
Location: 6 locations
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Status: Active
Location: 5 locations
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
Status: Active
Location: 3 locations
Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder
Status: Active
Location: 5 locations
Nab-paclitaxel followed by Gemcitabine Hydrochloride in Treating Pediatric Participants with Newly-Diagnostic, Relapsed or Refractory Solid Tumors
Status: Active
Location: 3 locations
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
Status: Active
Location: 2 locations
Nab-Paclitaxel and Gemcitabine Hydrochloride in Treating Teenagers or Young Adults with Recurrent or Refractory Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, or Soft Tissue Sarcoma
Status: Active
Location: 4 locations
Durvalumab in Combination with Chemotherapy in Treating Patients with Advanced Solid Tumors, DURVA+ Trial
Status: Active
Location: National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland
Ascorbic Acid and Combination Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, Clonal Cytopenia of Undetermined Significance and Chronic Myelomonocytic Leukemia
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
Gemcitabine and Nab-Paclitaxel With or Without ONT01 for the Treatment of Unresectable/Advanced or Metastatic Pancreatic Ductal Adenocarcinoma
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Retifanlimab with or without Gemcitabine and Docetaxel in Patients with Advanced, Unresectable or Metastatic Soft Tissue Sarcoma
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Focused Ultrasound with Low-Dose Gemcitabine to Increase Immune Control in Patients with Stage I-III Breast Cancer
Status: Active
Location: University of Virginia Cancer Center, Charlottesville, Virginia
Emavusertib in Combination with Cisplatin, Gemcitabine, and Durvalumab for the Treatment of Advanced Unresectable or Metastatic Biliary Tract Cancer
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer
Status: Active
Location: See ClinicalTrials.gov
Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients with Locally Advanced or Metastatic Kidney Cancer
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Biomarker-Driven Therapy and Immunotherapy in Screening Participants with Recurrent or Stage IV Non-Small Cell Lung Cancer (The Expanded Lung-MAP Screening Trial)
Status: Active
Location: 1119 locations
Microdevice for In Situ Candidate Drug Screening in Skin Lesions of T-Cell Lymphoma
Status: Active
Location: 2 locations